New myeloma drug combo aims to replace stem cell transplants
NCT ID NCT07428369
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test a new drug called linvoseltamab combined with standard chemotherapy drugs (bortezomib and lenalidomide) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal was to see if this combination, with or without a transplant, works better than the current standard treatment. However, the trial was withdrawn before any participants were enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
linvoseltamab (with bortezomib and lenalidomide)
What this could lead to
If successful, this could offer a new combination therapy for multiple myeloma that might reduce the need for stem cell transplants.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. The approach is still experimental and may not prove better than current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.